<DOC>
	<DOCNO>NCT00683670</DOCNO>
	<brief_summary>The purpose study investigate method use dendritic cell ( kind white blood cell ) vaccine stimulate immune system react melanoma cell .</brief_summary>
	<brief_title>Dendritic Cells ( White Blood Cells ) Vaccination Advanced Melanoma</brief_title>
	<detailed_description>Eligible patient provide write informed consent undergo apheresis collect blood mononuclear cell vaccine production . All patient give cyclophosphamide 300mg/m2 IV three day prior vaccine dose # 1 order deplete regulatory T cell . All patient receive mature DC dose vaccine . For dose patient receive autologous dendritic cell pulse 2 gp100 melanoma peptide ( G209-2M G280-9V ) plus additional 10 unique melanoma tumor-specific peptide . All patient receive booster dos mature DC . The DC vaccine give intravenously every three week total six vaccine dos . Peripheral blood ( 16 ml ) take weekly monitor immune response peptide tetramer assay . Apheresis repeat vaccine dose # 3 dose # 6 order collect PBMC immune monitoring . Restaging perform three six vaccine dos . Patients stable disease well ( partial response/complete response ) six dos eligible receive additional vaccination maintenance therapy every 2 month progression .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Unresectable stage III stage IV M1a/M1b/M1c melanoma include patient uveal melanoma Age ≥ 18 year Life expectancy ≥ 4 month ECOG performance status 02 At least 28 day prior treatment ( include adjuvant interferon ) except case BRAF inhibitor ( vemurafenib ) ; concurrent treatment BRAF inhibitor +/ MEK inhibitor permit Required initial laboratory value ( submit within 14 day prior registration ) : WBC &gt; 3,000/mm3 Hg ≥ 9.0 gm/dl Platelets &gt; 75,000/mm3 Serum Bilirubin &lt; 2.0 mg/dl Serum Creatinine &lt; 2.0 mg/dl Sexually active woman childbearing potential must use effective birth control trial least two month follow trial , sexually active men must willing avoid father new child receive therapy . Prior treatment one line cytotoxic chemotherapy ; prior treatment one line cytotoxic chemotherapy permit . Prior treatment target therapy ( ipilumumab , antiPD1 , BRAF inhibitor ) permit . Active untreated CNS metastasis Active infection Prior malignancy ( except nonmelanoma skin cancer ) within 3 year Pregnant nursing Concurrent treatment corticosteroid ; local ( inhaled topical ) steroid permit . Inability provide adequate informed consent Known allergy egg Prior history uveitis autoimmune inflammatory eye disease . Known positivity hepatitis BsAg , hepatitis C antibody , HIV antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>